TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03835884
Drug: AR-13503 42.4 Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye
Study: NCT03835884
Drug: AR-13503 63.6 Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
Study: NCT00459693
Drug: [11C]PBR28
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00874406
Drug: folfox4
Approvals — FDA: no, EMA: no, PMDA: no
Description: folfox4 will be done within 28 days after liver resection
Study: NCT02078102
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
Study: NCT02798991
Drug: GSK3179106
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
Study: NCT02798991
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
Study: NCT02133664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo lipoic acid and placebo oil
Study: NCT02833792
Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT01617135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00070252
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02956850
Drug: RO7020531
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7020531 will be administered as per schedule specified in the respective arm.
Study: NCT03177811
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT01668641
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01668641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03833570
Drug: BBC oral spray
Normalized name: SNAIL, UNSPECIFIED 18.05 g in 40 g / TITANIUM DIOXIDE 3.6 g in 40 g / ZINC OXIDE 2.52 g in 40 g / ARBUTIN 0.8 g in 40 g / ADENOSINE 0.016 g in 40 g TOPICAL CREAM [SKIN79 SNAIL NUTRITION BBCREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetics and anti-inflammatory agent
Study: NCT03833570
Drug: Oracure gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical analgesic gel
Study: NCT03515941
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
Study: NCT03515941
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 by IV (Arm 1 \& Arm 2)
Study: NCT02960646
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02606760
Drug: P-3073
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02606760
Drug: Vehicle of P-3073
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01560052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy
Study: NCT02819960
Drug: Probio-Tec® BG-VCap-6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
Study: NCT02819960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin
Study: NCT03340896
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
Study: NCT01048723
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were instructed to take RAD001 in the morning, at the same time each day.
Study: NCT00787137
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate-buffered saline
Study: NCT02488291
Drug: 0.25 sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: with different dosage
Study: NCT02488291
Drug: 0.5µg/ml sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5µg/ml sufentanil
Study: NCT00106691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
Study: NCT00989391
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study: NCT01424423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00989391
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
Study: NCT02594800
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
Study: NCT03353922
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT01294462
Drug: Acetylsalicylic acid ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose ASA
Study: NCT04342689
Drug: Dietary Supplement containing resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
Study: NCT00376805
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered intravenously 60 mg/kg days times 2 doses.
Study: NCT01424423
Drug: GSK1223249
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. Infusion
Study: NCT00928278
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, 300/150, single dose
Study: NCT00928278
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, 300/150, single dose
Study: NCT00004705
Drug: amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004705
Drug: uridine
Normalized name: Uridine
DrugBank: Uridine (DB02745)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00953680
Drug: losartan potassium (+) hydrochlorothiazide (HCTZ)
Normalized name: hydrochlorothiazide / losartan potassium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
Study: NCT04007289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
Study: NCT04433559
Drug: Placebo oral tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo in control group
Study: NCT00633789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, until progression
Study: NCT00613080
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1650 mg/m\^2/day orally 5 days/week during radiotherapy.
Study: NCT00613080
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1.
Study: NCT02845778
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each sachet contains 0.5 g
Study: NCT01058512
Drug: NOV-205
Normalized name: Dallergy Reformulated Nov 2011
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 4 treatment Groups with 10 patients in each group:~* Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~* Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~* Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~* Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days
Study: NCT04642924
Drug: SGM-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescence-guided surgery
Study: NCT01705158
Drug: carboplatin and liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
Study: NCT03342352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for epacadostat administered orally twice daily.
Study: NCT00145691
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049777
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03734029
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT04890587
Drug: AL8326 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.
Study: NCT00831701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo pill per day for 21 days or until stone expulsion
Study: NCT01605942
Drug: Placebo Drug Delivery System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
Study: NCT03130426
Drug: iGlarLixi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose is titrated to achieve fasting normoglycemia
Study: NCT00076336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine matching placebo or lamivudine matching placebo tablet.
Study: NCT01382004
Drug: Penicillin-G-benzathine
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
Study: NCT01382004
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window
Study: NCT03556098
Drug: Glucose-Dependent Insulin-Releasing Hormone[3-30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of GIP antagonist GIP\[3-30\]
Study: NCT00823992
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc once weekly
Study: NCT02673567
Drug: TEV-48125 - 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration Dose Regimen 1
Study: NCT02673567
Drug: TEV-48125 - 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration Dose Regimen 2
Study: NCT02673567
Drug: TEV-48125 - 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration Dose Regimen 3
Study: NCT02673567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03552211
Drug: biotin
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
Study: NCT00919867
Drug: SPD503
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Study: NCT00919867
Drug: SPD503 and VYVANSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
Study: NCT01920893
Drug: Placebo (for dupilumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection; Subcutaneous injection.
Study: NCT01933126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02181478
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
Study: NCT05735301
Drug: Drug
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: best drug conservative therapy could be uesd in patients who with no indication of surgery
Study: NCT00002627
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00159913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral; 3 times a day(TID)
Study: NCT04453813
Drug: Concurrent chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy
Study: NCT04364607
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IM NaCl 0.9% as a placebo
Study: NCT01143051
Drug: epinephrine inhalation aerosol
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 220 mcg/inhalation, 10 inhalations
Study: NCT01143051
Drug: epinephrine inhalation aerosol
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
Study: NCT01143051
Drug: epinephrine inhalation aerosol
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
Study: NCT01863134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02914548
Drug: OPA-15406
Normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
Study: NCT02914548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
Study: NCT00225589
Drug: Rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00872378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
Study: NCT01731730
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study: NCT01731730
Drug: AYX1 Injection 110 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mL solution for intrathecal injection with 110 mg of AYX1
Study: NCT01731730
Drug: AYX1 Injection 330 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mL solution for intrathecal injection with 330 mg of AYX1
Study: NCT02404922
Drug: Placebo for CTP-730
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01149486
Drug: Losartan potassium/Hydrochlorothiazide
Normalized name: losartan potassium/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/25 mg Tablets
Study: NCT01149486
Drug: Hyzaar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/25 mg Tablets
Study: NCT00320749
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will be give on days 8-21
Study: NCT02283515
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
Study: NCT01997814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
Study: NCT01562405
Drug: ACE-011
Normalized name: dibucaine 0.011 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection every 28 days, dose escalation levels from 15-45 mg
Study: NCT03067285
Drug: ELV/COBI/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
Study: NCT03067285
Drug: DTG/3TC/ABC + ELV/COBI/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
Study: NCT02233244
Drug: CTX-4430
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05782192
Drug: SAL067
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
Study: NCT05782192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
Study: NCT01680692
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of local anesthetic for post-operative analgesia.
Study: NCT01563289
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 times a day
Study: NCT01563289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day
Study: NCT00663286
Drug: IDP-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT00663286
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application for 12 weeks